Brain metastases are one of the most common neurologic complications of cancer. The
incidence is 9%–17% based on various studies, although the exact incidence is thought to …

Leptomeningeal disease has become increasingly prevalent as novel therapeutic
interventions extend the survival of cancer patients. Although a majority of leptomeningeal …

Background Dabrafenib plus trametinib improves clinical outcomes in BRAF V600-mutant
metastatic melanoma without brain metastases; however, the activity of dabrafenib plus …

Purpose: Melanoma brain metastases (MBM) and leptomeningeal melanoma metastases
(LMM) are two different manifestations of melanoma CNS metastasis. Here, we used single …

Background Brain metastases are common in patients with metastatic melanoma and
median overall survival from their diagnosis is typically 17–22 weeks. We assessed …

BACKGROUND: One of the most common and deadly complications of melanoma is brain
metastases. The outcomes of advanced melanoma patients who developed brain …

Leptomeningeal metastasis (LM) results from metastatic spread of cancer to the
leptomeninges, giving rise to central nervous system dysfunction. Breast cancer, lung …

This first German evidence-based guideline for cutaneous melanoma was developed under
the auspices of the German Dermatological Society (DDG) and the Dermatologic …

Background Ipilimumab improves survival of patients with metastatic melanoma, many of
whom develop brain metastases. Chemotherapy-induced release of tumour antigens might …

Leptomeningeal metastasis occurs in~ 5% of all patients with cancer and is the third most
common metastatic complication of the central nervous system. Staging of leptomeningeal …